Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Clinical Trial of Umbilical Cord Mesenchymal Stem Cells in Subacute Ischemic Stroke

The goal of this clinical trial is to evaluate the efficacy, safety, and pharmacodynamic characteristics of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in adults with ischemic stroke in the anterior circulation during the recovery phase. Researchers will compare hUC-MSCs to a placebo to determine whether hUC-MSCs treatment is effective in treating recovery-phase anterior circulation ischemic stroke.

Participants needed: 86
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Shanghai IxCell Biotechnology Co., LTDUpdated: Sep 29, 2025Locations: 1
Eligibility criteria

Age ≥18 years and ≤70 years, regardless of gender. [+4]

People who had a history of epilepsy, dementia, Parkinson's disease, severe depr... [+4]

Read more
Status: Not yet recruiting

Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-P) in the Treatment of CTD-ILD

To evaluate the safety and tolerability of IxCell hUC-MSC-P in the treatment of patients with connective tissue disease-related interstitial lung disease. To evaluate the efficacy, pharmacokinetics and immunogenicity of IxCell hUC-MSC-P in the treatment of connective tissue disease-associated interstitial lung disease (CTD-ILD).

Participants needed: 18
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Shanghai IxCell Biotechnology Co., LTDUpdated: Feb 14, 2025Locations: 1
Eligibility criteria

Both sexes, aged 18-80 years; [+10]

The patients were diagnosed with other lung diseases other than SSc-ILD, such as... [+20]

Read more
Status: Recruiting

Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

To evaluate the efficacy of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis. To evaluate the safety of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis.

Participants needed: 398
Trial details
Phase: Phase 3Age: 40-80Biological sex: AllType: InterventionalSponsor: Shanghai IxCell Biotechnology Co., LTDUpdated: Dec 6, 2024Locations: 1
Eligibility criteria

Patients diagnosed with knee osteoarthritis according to the "Guidelines for the... [+6]

Patients diagnosed with secondary knee osteoarthritis; [+23]

Read more